Understand the source comparison
Is Glow Stack Safe Long Term Use: Clinical Evidence Comparison
Collagen peptides (hydrolysed) 24+ months continuous in osteoarthritis trials (published in Journal of Medicinal Food) Negligible—oral bioavailability limits systemic exposure; renal clearance efficient No cycling required for oral forms; injectable forms bene
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Collagen peptides (hydrolysed)
- 24+ months continuous in osteoarthritis trials (published in Journal of Medicinal Food)
- Negligible—oral bioavailability limits systemic exposure; renal clearance efficient
- No cycling required for oral forms; injectable forms benefit from 12-week cycles
- Safest component for extended use—minimal immune interaction
- L-glutathione (reduced form)
- 18 months in clinical liver disease protocols (Hepatology journal)
- Oxidative stress rebound if discontinued abruptly; potential for tolerance at >1g daily
- 10 weeks on, 4 weeks off at research doses above 600mg daily
- Safe long-term but efficacy plateaus without cycling
- Thymalin (thymus extract peptides)
- 12 months in immunosenescence studies (Biogerontology)
- Antibody formation window begins around week 16; immune modulation requires monitoring
- 8 weeks on, 6 weeks off to preserve immune responsiveness
- Requires structured cycling—continuous use reduces benefit
- Growth-factor mimetics (e.g., MK 677)
- 24 months in sarcopenia trials (Journal of Clinical Endocrinology)
- IGF-1 elevation sustainability; insulin sensitivity changes at prolonged high-dose
- 12 weeks on, 4–6 weeks off; bloodwork recommended at 6-month intervals
- Safe with monitoring—cycle discipline prevents metabolic adaptation
- This table reflects peer-reviewed trial durations and observed endpoints. Glow Stack protocols combining these components inherit the longest safe-use duration of the most conservative compound unless cycling mitigates individual risks.